Skip to content
Study details
Enrolling now

Cancer Treatment Informed by the Molecular Tumor Board At Dartmouth

Dartmouth-Hitchcock Medical Center
NCT IDNCT05405413ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

192

Study length

about 5.8 years

Ages

18+

Locations

1 site in NH

About this study

Researchers are testing whether treatment recommendations from a Molecular Tumor Board impact how doctors make decisions about cancer treatment at Dartmouth Cancer Center. The trial will involve patients whose tumors are genetically profiled and who meet specific eligibility criteria. Doctors will be asked to complete surveys about how the Molecular Tumor Board's evaluation influenced their treatment choices.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Treatment recommendations made by Molecular Tumor Board
PhasePhase 2

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Number of participants with progression-free survival after Molecular Tumor Board recommendations were made., Time to treatment failure

Body systems

Oncology